Question explored with the scientific record
how does one cure their ED
The short version: erectile dysfunction is often a signal of underlying vascular or metabolic disease, and the evidence supports treating those root causes alongside the symptom.
Erectile dysfunction is not a disease itself. It is a symptom of something else: poor blood flow, damaged nerves, hormone imbalance, or psychological distress. The evidence here shows that ED is tightly linked to cardiovascular disease, diabetes, and metabolic syndrome [5][9]. In one study of men with type 2 diabetes and ED, about 52% already had cardiovascular disease [9]. Another study found that men with ED and higher comorbidity scores were older and had worse erectile function [8]. This means the first question is not "which pill?" but "what is causing this?"
The most studied treatments are PDE5 inhibitors like sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). In a 1999 study of 308 men, sildenafil produced a 65% satisfaction rate overall, but only 41% in men with severe ED [1]. Tadalafil taken daily improved first-attempt success from about 29% on placebo to 55% on the 5 mg dose [2]. Vardenafil also worked in men who had not responded to sildenafil, raising their erectile function score from 9.3 to 17.6 over 12 weeks [3]. These drugs work by increasing blood flow to the penis. They do not fix the underlying cause.
| Treatment | Group | Success or improvement rate |
|---|---|---|
| Sildenafil (1999) | All men with ED | 65% satisfied |
| Sildenafil (1999) | Severe ED only | 41% satisfied |
| Tadalafil 5 mg daily | First attempt | 55% success |
| Tadalafil 5 mg daily | Subsequent attempts | 86% success |
| Vardenafil (sildenafil non-responders) | EF score change | 9.3 to 17.6 |
For men with insulin resistance and a poor response to sildenafil, adding metformin improved IIEF scores from 14.3 to 19.8 over 4 months, while the placebo group stayed flat at 14.3 [4]. This matters because insulin resistance damages the endothelium, the lining of blood vessels, and ED is often the first sign of that damage [7]. Testosterone replacement also helped men with type 2 diabetes and low testosterone, but the improvement was modest: about one point on the IIEF scale over 30 weeks [6].
The evidence does not support a single "cure." It supports a workup: check blood sugar, blood pressure, lipids, and testosterone. Treat what is abnormal. Add a PDE5 inhibitor if needed. The drugs are effective for symptom relief but do not reverse the vascular disease that caused the ED. The best long-term approach is to treat the underlying condition, not just the erection.
My call: ED is treatable with PDE5 inhibitors, but the real cure is fixing the metabolic and vascular drivers. Confidence: high for symptom relief with drugs, moderate for the root-cause approach because few long-term trials compare lifestyle intervention to drug therapy head-to-head.
Sources used 9
-
CLINICAL EFFICACY OF SILDENAFIL CITRATE BASED ON ETIOLOGY AND RESPONSE TO PRIOR TREATMENT
This study evaluates the clinical efficacy of sildenafil citrate in treating erectile dysfunction, identifying predictors of satisfactory outcomes based on etiology and prior treatment responses.
DOI: 10.1097/00005392-199909010-00024 -
Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success
This study evaluates the reliability of tadalafil taken once daily for erectile dysfunction, demonstrating significantly higher rates of successful intercourse and satisfaction compared to placebo after initial success.
DOI: 10.1038/ijir.2009.29 -
Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double‐blind, 12‐week, flexible‐dose, placebo‐controlled erectile dysfunction clinical trial
This study demonstrates that vardenafil is an effective and generally safe treatment for erectile dysfunction in men who have previously been unresponsive to sildenafil.
DOI: 10.1111/j.1464-410X.2004.05161.x -
Addition of Metformin to Sildenafil Treatment for Erectile Dysfunction in Eugonadal Nondiabetic Men With Insulin Resistance. A Prospective, Randomized, Double‐Blind Pilot Study
This study evaluates the effect of metformin on erectile dysfunction in eugonadal nondiabetic men with insulin resistance who had a poor response to sildenafil, finding that metformin significantly improved erectile function and reduced insulin resistance compared to placebo.
DOI: 10.2164/jandrol.111.013714 -
Irreversible antidepressant-induced sexual dysfunction: what do we know so far?
In a retrospective review of 255 sexual dysfunction cases at a Spanish primary care centre, 75.69% were erectile dysfunction, with an average 1.95-year diagnostic delay and frequent cardiovascular, metabolic, and psychiatric comorbidities.
DOI: 10.1192/j.eurpsy.2025.2296 -
Testosterone Replacement Therapy with Long‒Acting Testosterone Undecanoate Improves Sexual Function and Quality‒of‒Life Parameters vs. Placebo in a Population of Men with Type 2 Diabetes
In men with type 2 diabetes and hypogonadism, testosterone undecanoate improved sexual function and quality of life, with greater improvement in less obese men and those without depression; there was no evidence of increased cardiovascular events or a baseline-testosterone respo…
DOI: 10.1111/jsm.12146 -
Mechanistic link between erectile dysfunction and systemic endothelial dysfunction in type 2 diabetic rats
This study investigates the early molecular mechanisms linking erectile dysfunction (ED) and systemic endothelial dysfunction in type 2 diabetic rats, revealing that oxidative stress and endothelial nitric oxide synthase (eNOS) uncoupling occur in the penis before any changes in…
DOI: 10.1111/andr.12218 -
Is Erectile Dysfunction a Reliable Proxy of General Male Health Status? The Case for the International Index of Erectile Function—Erectile Function Domain
In men with erectile dysfunction, higher Charlson Comorbidity Index scores were independently associated with greater erectile dysfunction severity and older age, while no clear association was found with penile Doppler ultrasound parameters.
DOI: 10.1111/j.1743-6109.2012.02869.x -
The prevalence of cardiovascular disease in male patients with type 2 diabetes mellitus and erectile dysfunction, along with an assessment of shared cardiovascular risk factors
In male patients with type 2 diabetes mellitus and erectile dysfunction, cardiovascular disease is highly prevalent (about 52%), and those with CVD are older and more likely to smoke, drink alcohol, and have peripheral neuropathy, suggesting erectile dysfunction may signal eleva…
DOI: 10.53730/ijhs.v9n2.15655